Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform

Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform
5 May 2022
PharmaShots – View full story